Insider Trading Alert - LLY, WPX And AWAY Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 4, 2014, 122 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $58.00 to $13,354,526.14.

Highlighted Stocks Traded by Insiders:

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 200,000 shares at $63.99 on Sept. 4, 2014. Following this transaction, the 10% Owner owned 133.1 million shares meaning that the stake was reduced by 0.15% with the 200,000-share transaction.

The shares most recently traded at $64.14, up $0.15, or 0.23% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 1.2 million
  • 24-Week # shares bought: 17,157
  • 24-Week # shares sold: 2.4 million

The average volume for Eli Lilly and has been 3.6 million shares per day over the past 30 days. Eli Lilly and has a market cap of $71.7 billion and is part of the health care sector and drugs industry. Shares are up 25.92% year-to-date as of the close of trading on Thursday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The stock currently has a dividend yield of 3.06%. The company has a P/E ratio of 20.4. Currently, there are 6 analysts who rate Eli Lilly and a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief